{"id":"recombinant-interferon-alfa-2b","safety":{"commonSideEffects":[{"rate":"50-90%","effect":"Flu-like symptoms"},{"rate":"30-70%","effect":"Fatigue"},{"rate":"20-50%","effect":"Headache"},{"rate":"20-50%","effect":"Myalgia"},{"rate":"10-30%","effect":"Chills"},{"rate":"10-30%","effect":"Nausea"},{"rate":"5-20%","effect":"Vomiting"},{"rate":"5-20%","effect":"Diarrhea"},{"rate":"5-20%","effect":"Abdominal pain"},{"rate":"5-20%","effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL1201558","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It does this by binding to the interferon-alpha receptor, which triggers a cascade of signaling events that ultimately lead to the production of antiviral and antiproliferative proteins. This helps to slow down or stop the growth of cancer cells and reduce the severity of viral infections.","oneSentence":"Recombinant interferon alfa-2b works by stimulating the body's immune system to fight viral infections and cancer.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:39.629Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hairy cell leukemia"},{"name":"Chronic myelogenous leukemia"},{"name":"Multiple myeloma"},{"name":"Melanoma"},{"name":"Kaposi's sarcoma"}]},"trialDetails":[{"nctId":"NCT02506153","phase":"PHASE3","title":"Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-10","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma","enrollment":1301},{"nctId":"NCT00569127","phase":"PHASE3","title":"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2007-12-01","conditions":"Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm","enrollment":427},{"nctId":"NCT07468916","phase":"PHASE2","title":"Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2026-03-29","conditions":"Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm","enrollment":35},{"nctId":"NCT02737046","phase":"PHASE2","title":"Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma","status":"COMPLETED","sponsor":"University of Miami","startDate":"2016-12-12","conditions":"Adult T-cell Leukemia-Lymphoma, ATLL","enrollment":15},{"nctId":"NCT04380545","phase":"PHASE1, PHASE2","title":"Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-01-13","conditions":"Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8","enrollment":15},{"nctId":"NCT06545955","phase":"PHASE3","title":"A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Ferring Pharmaceuticals","startDate":"2024-10-01","conditions":"Non-muscle Invasive Bladder Cancer With Carcinoma in Situ","enrollment":250},{"nctId":"NCT07445893","phase":"NA","title":"A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV","status":"NOT_YET_RECRUITING","sponsor":"Duan Minghui","startDate":"2026-02-24","conditions":"Polycythemia Vera (PV)","enrollment":30},{"nctId":"NCT00003641","phase":"PHASE3","title":"High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"1999-03-25","conditions":"Melanoma (Skin)","enrollment":1150},{"nctId":"NCT04093323","phase":"PHASE2","title":"Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2024-11-13","conditions":"HLA-A2 Positive Cells Present, Refractory Melanoma","enrollment":1},{"nctId":"NCT01274338","phase":"PHASE3","title":"Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-05-25","conditions":"Melanoma of Unknown Primary, Recurrent Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7","enrollment":1673},{"nctId":"NCT04379518","phase":"PHASE1, PHASE2","title":"Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2020-11-17","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed","enrollment":4},{"nctId":"NCT00539591","phase":"PHASE2","title":"Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2008-05-09","conditions":"Malignant Melanoma","enrollment":29},{"nctId":"NCT01708941","phase":"PHASE2","title":"Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-01-18","conditions":"Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7","enrollment":88},{"nctId":"NCT07231276","phase":"PHASE4","title":"Prospective Cohort Study on PEG-IFN-α-2b in Improving Clinical Cure Rate of Pediatric Patients With Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2026-01-01","conditions":"HBV, Chronic Hepatitis B Virus","enrollment":113},{"nctId":"NCT02370329","phase":"PHASE2","title":"P1101 in Treating Patients With Myelofibrosis","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2015-08-12","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":11},{"nctId":"NCT03899987","phase":"PHASE2","title":"Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2019-11-29","conditions":"Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8","enrollment":12},{"nctId":"NCT04418219","phase":"PHASE1, PHASE2","title":"Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"Thomas Jefferson University","startDate":"2020-12-21","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8","enrollment":""},{"nctId":"NCT06137950","phase":"PHASE1","title":"Interferon Alpha Therapy for Cervical CINI and HPV Infection","status":"COMPLETED","sponsor":"Mongolian National University of Medical Sciences","startDate":"2023-11-07","conditions":"Cervical Dysplasia, HPV Infection","enrollment":60},{"nctId":"NCT06900166","phase":"PHASE4","title":"Pegylated Interferon Alfa-2b in Reducing Relapse Rates After Nucleos(t)ide Analogue Withdrawal in HBeAg-negative CHB Patients with Low Level HBsAg","status":"NOT_YET_RECRUITING","sponsor":"Huashan Hospital","startDate":"2025-04-01","conditions":"Chronic Hepatitis B","enrollment":360},{"nctId":"NCT06777173","phase":"NA","title":"Clinical Study of Antiviral Therapy Combined With Novel Immunotherapy for CHB in Adults","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Ditan Hospital","startDate":"2023-12-01","conditions":"Chronic Hepatitis b, Immunotherapy","enrollment":180},{"nctId":"NCT02001818","phase":"PHASE2","title":"Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia","status":"COMPLETED","sponsor":"Australasian Leukaemia and Lymphoma Group","startDate":"2014-04-11","conditions":"Chronic Myeloid Leukaemia","enrollment":60},{"nctId":"NCT04226950","phase":"PHASE2","title":"Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Childhood and Adolescent Essential Thrombocythemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2020-01-10","conditions":"Essential Thrombocytopenia","enrollment":40},{"nctId":"NCT05395507","phase":"PHASE2","title":"Pegylated Interferon Alfa-2b Versus Interferon Alfa Therapy in Adult Essential Thrombocythemia","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-06-01","conditions":"Essential Thrombocytopenia","enrollment":194},{"nctId":"NCT01353911","phase":"PHASE2","title":"Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-06-27","conditions":"Hepatitis C, Chronic","enrollment":368},{"nctId":"NCT04081389","phase":"PHASE1","title":"Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2019-12-06","conditions":"Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8","enrollment":9},{"nctId":"NCT03599453","phase":"EARLY_PHASE1","title":"Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2019-01-09","conditions":"Triple -Negative Breast Cancer, Estrogen Receptor Negative, HER2/Neu Negative","enrollment":8},{"nctId":"NCT00049530","phase":"PHASE2","title":"PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2004-01-13","conditions":"Melanoma (Skin)","enrollment":32},{"nctId":"NCT05922306","phase":"EARLY_PHASE1","title":"Efficacy of NA Combined With PEG-IFN-α2b in the Continuous Versus Pulsed Treatment of Patients With Chronic Hepatitis B","status":"RECRUITING","sponsor":"Anhui Medical University","startDate":"2023-07","conditions":"Hepatitis B, Chronic","enrollment":1084},{"nctId":"NCT00003444","phase":"PHASE3","title":"Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1999-03-29","conditions":"Melanoma (Skin)","enrollment":167},{"nctId":"NCT00134030","phase":"PHASE3","title":"Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2005-11-14","conditions":"Localized Osteosarcoma, Metastatic Osteosarcoma","enrollment":1334},{"nctId":"NCT01359956","phase":"PHASE3","title":"Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma","status":"COMPLETED","sponsor":"National Cancer Institute, Naples","startDate":"2002-04","conditions":"Malignant Melanoma, Recurrent Melanoma","enrollment":269},{"nctId":"NCT05806918","phase":"PHASE3","title":"Non-inferiority Study of ZK-A03 in Treatment of Herpes Zoster Before and After the Alteration of the Active Ingredient Manufacturer","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2023-04-01","conditions":"Herpes Zoster","enrollment":368},{"nctId":"NCT02634294","phase":"PHASE2, PHASE3","title":"Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT","status":"COMPLETED","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2015-08","conditions":"Hematological Neoplasms, Recurrence","enrollment":30},{"nctId":"NCT02089685","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-03-17","conditions":"Renal Cell Carcinoma, Melanoma","enrollment":295},{"nctId":"NCT05466565","phase":"","title":"Antiviral Therapy for Patients With Liver Cancer After Surgery","status":"RECRUITING","sponsor":"Xiangya Hospital of Central South University","startDate":"2021-12-01","conditions":"Hepatocellular Carcinoma","enrollment":360},{"nctId":"NCT04669015","phase":"PHASE3","title":"Phase 3 Inhaled Novaferon Study in Hospitalized Patients With Moderate to Severe COVID-19","status":"UNKNOWN","sponsor":"Genova Inc.","startDate":"2021-06-10","conditions":"Covid19","enrollment":914},{"nctId":"NCT04943679","phase":"","title":"Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-06-15","conditions":"Hepatocellular Carcinoma","enrollment":15},{"nctId":"NCT00003656","phase":"PHASE2","title":"Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"1999-01","conditions":"Kidney Cancer","enrollment":26},{"nctId":"NCT05172037","phase":"PHASE3","title":"Novaferon in Non-hospitalized Adult Patients With Mild COVID-19","status":"UNKNOWN","sponsor":"Genova Inc.","startDate":"2021-10-28","conditions":"Covid19","enrollment":222},{"nctId":"NCT03403634","phase":"PHASE2","title":"Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2018-04-19","conditions":"Metastatic Carcinoma in the Liver, Recurrent Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v7","enrollment":19},{"nctId":"NCT04708158","phase":"PHASE3","title":"Novaferon for COVID-19 Treatment Trial (NCTT-005)","status":"UNKNOWN","sponsor":"Genova Inc.","startDate":"2021-03-25","conditions":"Covid19","enrollment":385},{"nctId":"NCT02343224","phase":"PHASE2","title":"Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas","status":"COMPLETED","sponsor":"Emory University","startDate":"2014-11","conditions":"Juvenile Pilocytic Astrocytomas, Optic Pathway Gliomas","enrollment":9},{"nctId":"NCT02323659","phase":"PHASE4","title":"Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas","status":"TERMINATED","sponsor":"Polish Lymphoma Research Group","startDate":"2014-06-01","conditions":"Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides","enrollment":100},{"nctId":"NCT00000694","phase":"PHASE1","title":"A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Sarcoma, Kaposi, HIV Infections","enrollment":18},{"nctId":"NCT00006325","phase":"PHASE1","title":"Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT00001114","phase":"PHASE2","title":"The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Sarcoma, Kaposi, HIV Infections","enrollment":90},{"nctId":"NCT00015652","phase":"NA","title":"Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV Coinfection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis C","enrollment":24},{"nctId":"NCT03056599","phase":"PHASE1","title":"Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Presage Biosciences","startDate":"2016-12-15","conditions":"Soft Tissue Sarcoma Adult","enrollment":23},{"nctId":"NCT03294798","phase":"PHASE1, PHASE2","title":"Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient","status":"COMPLETED","sponsor":"Tianjin SinoBiotech Ltd.","startDate":"2017-06-13","conditions":"Hepatitis B Virus","enrollment":11},{"nctId":"NCT00398450","phase":"PHASE1","title":"Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2006-02","conditions":"Melanoma (Skin)","enrollment":12},{"nctId":"NCT02339324","phase":"PHASE1","title":"Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b","status":"COMPLETED","sponsor":"Yana Najjar","startDate":"2015-03-06","conditions":"Melanoma","enrollment":31},{"nctId":"NCT01710501","phase":"PHASE2","title":"A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-07","conditions":"Chronic Hepatitis C (CHC)","enrollment":87},{"nctId":"NCT03178123","phase":"PHASE2","title":"The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery","status":"UNKNOWN","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2017-05-31","conditions":"Mucosal Melanoma","enrollment":220},{"nctId":"NCT00237484","phase":"PHASE3","title":"Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07-18","conditions":"Hepatitis C, Chronic","enrollment":89},{"nctId":"NCT00498979","phase":"PHASE1","title":"Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2007-05","conditions":"Stage IV Melanoma","enrollment":22},{"nctId":"NCT02151448","phase":"PHASE1, PHASE2","title":"αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies","status":"COMPLETED","sponsor":"David Bartlett","startDate":"2014-07","conditions":"Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma, Peritoneal Carcinomatosis","enrollment":64},{"nctId":"NCT02174172","phase":"PHASE1","title":"A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-08-18","conditions":"Solid Cancers","enrollment":158},{"nctId":"NCT00919633","phase":"PHASE2","title":"Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C","status":"COMPLETED","sponsor":"Medtronic Corporate Technologies and New Ventures","startDate":"2009-06","conditions":"Hepatitis C","enrollment":116},{"nctId":"NCT03547154","phase":"PHASE2, PHASE3","title":"Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1998-10-22","conditions":"Chronic Myelogenous Leukemia","enrollment":344},{"nctId":"NCT03552549","phase":"PHASE2, PHASE3","title":"SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1998-08-05","conditions":"Melanoma","enrollment":126},{"nctId":"NCT03554005","phase":"PHASE1","title":"Extended Administration of Polyethylene Glycol (PEG) Interferon Alfa-2b in Participants With Solid Tumors (C/I97-349/MK-4031-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1997-12-29","conditions":"Neoplasms","enrollment":29},{"nctId":"NCT00004088","phase":"PHASE2","title":"Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"1999-04-13","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":77},{"nctId":"NCT01603212","phase":"PHASE1","title":"Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-07-18","conditions":"Melanoma","enrollment":6},{"nctId":"NCT03537274","phase":"PHASE2, PHASE3","title":"Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1997-08-05","conditions":"Hepatitis C","enrollment":1224},{"nctId":"NCT01100528","phase":"PHASE2","title":"Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2009-11-11","conditions":"Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma","enrollment":38},{"nctId":"NCT03833362","phase":"PHASE3","title":"Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2014-05-07","conditions":"Hepatitis C","enrollment":420},{"nctId":"NCT00724061","phase":"NA","title":"Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2008-09","conditions":"Lymphoma","enrollment":7},{"nctId":"NCT00629200","phase":"PHASE1","title":"Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-09-13","conditions":"Advanced Cancer, Solid Tumors","enrollment":33},{"nctId":"NCT01460875","phase":"NA","title":"Recombinant Interferon Alfa-2b in Treating Patients With Melanoma","status":"COMPLETED","sponsor":"William Carson","startDate":"2008-04-22","conditions":"Stage IA Skin Melanoma, Stage IB Skin Melanoma, Stage IIA Skin Melanoma","enrollment":34},{"nctId":"NCT00038376","phase":"PHASE2","title":"Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1990-05-08","conditions":"Lymphoma, T-Cell, Mycosis Fungoides, Hematologic Neoplasms","enrollment":56},{"nctId":"NCT01606800","phase":"PHASE4","title":"Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-01-01","conditions":"Hepatitis C, Chronic","enrollment":45},{"nctId":"NCT01866553","phase":"PHASE2","title":"Nilotinib Plus Pegylated Interferon-α2b in CML","status":"TERMINATED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2013-04","conditions":"Chronic Myeloid Leukemia","enrollment":20},{"nctId":"NCT01608594","phase":"PHASE1","title":"Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma","status":"COMPLETED","sponsor":"Diwakar Davar","startDate":"2013-05-21","conditions":"Melanoma","enrollment":30},{"nctId":"NCT01641926","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-26","conditions":"Hepatitis B, Chronic","enrollment":402},{"nctId":"NCT02155322","phase":"PHASE2","title":"A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-08-19","conditions":"Melanoma","enrollment":33},{"nctId":"NCT01636960","phase":"PHASE1","title":"A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-25","conditions":"Malignant Melanoma","enrollment":9},{"nctId":"NCT01945294","phase":"PHASE3","title":"Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-10","conditions":"Hepatitis C, Chronic","enrollment":257},{"nctId":"NCT00090870","phase":"PHASE2","title":"PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer","status":"TERMINATED","sponsor":"Medical University of South Carolina","startDate":"2002-04","conditions":"Kidney Cancer","enrollment":10},{"nctId":"NCT02185261","phase":"NA","title":"Interferon α for the Therapy of Minimal Residual Disease","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2014-06","conditions":"Leukemia","enrollment":81},{"nctId":"NCT02360592","phase":"PHASE4","title":"Combination Therapy With Interferon Plus Interleukin 2 and Hepatitis B Vaccine in Chronic Hepatitis B Patients","status":"COMPLETED","sponsor":"Tongji Hospital","startDate":"2013-06","conditions":"Hepatitis B, Chronic","enrollment":94},{"nctId":"NCT00854581","phase":"PHASE4","title":"Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma","status":"TERMINATED","sponsor":"University of Miami","startDate":"2007-11","conditions":"Lymphoma, Precancerous/Nonmalignant Condition","enrollment":13},{"nctId":"NCT01943422","phase":"PHASE1","title":"Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma","status":"COMPLETED","sponsor":"John Kirkwood","startDate":"2013-10","conditions":"Melanoma","enrollment":7},{"nctId":"NCT00014261","phase":"PHASE1","title":"Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2000-10","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":""},{"nctId":"NCT01658813","phase":"PHASE2","title":"5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer","status":"COMPLETED","sponsor":"Western Regional Medical Center","startDate":"2012-07","conditions":"Gastrointestinal Cancer Metastatic, Renal Cell Cancer Metastatic, Non Small Cell Lung Cancer Metastatic","enrollment":18},{"nctId":"NCT00311558","phase":"PHASE1","title":"Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2005-10","conditions":"Cancer","enrollment":18},{"nctId":"NCT00262951","phase":"PHASE2","title":"Chemoradiation in Locally Advanced Pancreatic Cancer","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2005-01","conditions":"Pancreatic Cancer","enrollment":23},{"nctId":"NCT00005984","phase":"PHASE2","title":"Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2000-08","conditions":"Leukemia","enrollment":22},{"nctId":"NCT02199327","phase":"PHASE4","title":"Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia","status":"COMPLETED","sponsor":"Coordinación de Investigación en Salud, Mexico","startDate":"2014-05","conditions":"Conjunctival Intraepithelial Neoplasia, Corneal Intraepithelial Neoplasia","enrollment":18},{"nctId":"NCT00006244","phase":"PHASE2","title":"Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2000-02","conditions":"Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma","enrollment":36},{"nctId":"NCT00179413","phase":"PHASE4","title":"Study of Long-term Peg Intron vs. Colchicine in Non-responders.","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2000-01-15","conditions":"Hepatitis C Virus, Advanced Fibrosis, Cirrhosis","enrollment":549},{"nctId":"NCT00610857","phase":"PHASE2","title":"Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma","status":"COMPLETED","sponsor":"Ahmad Tarhini","startDate":"2006-11","conditions":"Melanoma","enrollment":37},{"nctId":"NCT01409174","phase":"PHASE1","title":"IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-02","conditions":"Melanoma","enrollment":19},{"nctId":"NCT00317746","phase":"PHASE3","title":"Trial of Citalopram for the Prevention of Depression","status":"COMPLETED","sponsor":"Marina Klein","startDate":"2006-11","conditions":"Depression, HIV Infections, Hepatitis C","enrollment":76},{"nctId":"NCT02781753","phase":"PHASE1","title":"Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Chinese Healthy Volunteers","status":"COMPLETED","sponsor":"Tianjin SinoBiotech Ltd.","startDate":"2016-04-07","conditions":"Healthy","enrollment":34},{"nctId":"NCT00493805","phase":"PHASE4","title":"Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-04","conditions":"Hepatitis C, Chronic, Insulin Resistance","enrollment":59},{"nctId":"NCT00423800","phase":"PHASE3","title":"Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12","conditions":"Hepatitis C, Chronic","enrollment":56},{"nctId":"NCT00959699","phase":"PHASE2","title":"A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"HIV Infections, Hepatitis C, HCV Infection","enrollment":99},{"nctId":"NCT00708500","phase":"PHASE3","title":"Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Hepatitis C, Chronic","enrollment":404},{"nctId":"NCT00686777","phase":"PHASE4","title":"Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01","conditions":"Hepatitis C, Chronic","enrollment":75},{"nctId":"NCT00863109","phase":"","title":"Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04","conditions":"Hepatitis C, Chronic, Genotype 1, HCV-1","enrollment":133}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":89,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IFN 2b","Alfatronol","Bioferon","Bioferon (TM)","Glucoferon"],"phase":"phase_3","status":"active","brandName":"recombinant interferon alfa-2b","genericName":"recombinant interferon alfa-2b","companyName":"Case Comprehensive Cancer Center","companyId":"case-comprehensive-cancer-center","modality":"Biologic","firstApprovalDate":"","aiSummary":"Recombinant interferon alfa-2b works by stimulating the body's immune system to fight viral infections and cancer. Used for Hairy cell leukemia, Chronic myelogenous leukemia, Multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}